{"entity":{"id":"nct01057069","kind":"trial","name":"Neo Adjuvant Chemotherapy in Triple Negative Breast Cancer","aka":["neo-TN"],"tldr":"A phase 2/3 trial of carboplatin, paclitaxel / nab-paclitaxel, doxorubicin, cyclophosphamide and other drugs in triple-negative breast cancer, run by The Netherlands Cancer Institute, active but no longer recruiting.","summary":"Neo Adjuvant Chemotherapy in Triple Negative Breast Cancer is a phase 2/3, randomised interventional study registered as NCT01057069 by The Netherlands Cancer Institute, with a registry enrolment figure of 310 participants, started 2010-01 and due to reach its primary completion in 2023-06. Interventions recorded: Carboplatin and Paclitaxel; Doxorubicin, cyclophosphamide; Doxorubicin, cyclophosphamide, carboplatin, thiotepa, cyclophosphamide. Conditions listed: Breast Cancer. Sites: Netherlands. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT01057069","url":"https://clinicaltrials.gov/study/NCT01057069"}],"tags":["ctgov-ingest","tnbc-deep-dive"],"related":[],"cancers":["tnbc-early"],"sections":[],"technologies":["cytotoxic-chemotherapy","platinum"],"targets":[],"drugs":["carboplatin","paclitaxel","doxorubicin","cyclophosphamide","thiotepa"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT01057069","phase":"2/3","setting":"Randomized Phase II/III Study of Individualized Neoadjuvant Chemotherapy in ' Triple Negative' Breast Tumors","sponsor":"The Netherlands Cancer Institute","enrolled":310,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct01057069/","neighbours":{"cancer":[{"id":"tnbc-early","kind":"cancer","name":"Early triple-negative breast cancer","route":"/cancers/tnbc-early/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"platinum","kind":"technology","name":"Platinum agents","route":"/technologies/platinum/"}],"drug":[{"id":"carboplatin","kind":"drug","name":"Carboplatin","route":"/drugs/carboplatin/"},{"id":"cyclophosphamide","kind":"drug","name":"Cyclophosphamide","route":"/drugs/cyclophosphamide/"},{"id":"doxorubicin","kind":"drug","name":"Doxorubicin","route":"/drugs/doxorubicin/"},{"id":"paclitaxel","kind":"drug","name":"Paclitaxel / nab-paclitaxel","route":"/drugs/paclitaxel/"},{"id":"thiotepa","kind":"drug","name":"Thiotepa","route":"/drugs/thiotepa/"}],"term":[{"id":"tnbc-trials-open-today","kind":"term","name":"Triple-negative breast cancer trials open today (registry snapshot and UK sites)","route":"/terms/tnbc-trials-open-today/"}]}}